Exciting news! The agenda for #CRAACO2024 is now live on our website.
🔗 https://lnkd.in/eRuf_Ji7
Check out this year’s key topics, including how to help patients access clinical research, bridging the gap between research and care, and much more at CRAACOevent.com
To make clinical trial programs more effective, there needs to be a strong understanding of the patient journey in a real-world setting and ensure we’re measuring endpoints that matter to them.
THREAD has a comprehensive approach that improves clinical research programs and provides a deeper understanding of the patient. Researchers can capture data from the wide range of sources that the patient touches and improve their understanding of the effectiveness of the research intervention.
Learn more about how we do this: https://bit.ly/3ScFnTc#realworld#RWD#datacollection#RWE#tokenization
This fact sheet includes information on the clinical status of cell-based therapies and clinical trials for #ALS for clinicians, scientists, and the public. Explore the fact sheet and share with your network.
Download the ALS fact sheet here 👉 https://ow.ly/78E550QUqAM
Thanks to the Clinials team, clients and clinical trial participants who have contributed during 2023 to the mission to
🙋♀️ Make Research more Patient Centric
⬆ Accelerate the rate of research
👨⚕️ Help research make an impact faster
#clinicaltrials#clinicalresearch
As leaders in #RareDisease research, we know that patients living with these conditions must overcome unique challenges – and thus, require unique solutions. We are committed to leading the way by applying a deep understanding of the patient experience to our clinical trial design. Learn how: http://spr.ly/6046Z0HEO
This was a great article to write - and I learnt a lot from Rachel Bruce, Kim Kelly and Lindsay Hughes in the process. In here we argue that the patient experiences of disease and treatment (normally included in a disease-level conceptual model) should really be contextualized in and supplemented with (a) an understanding of perceptions of (and associated behaviours related to) treatment/care, and (b) demographic/psychosocial variables which may act as enablers and constrainers of their experiences. Although this is logical and sensical, it is rarely done in pharmaceutical drug development. See Figure 5 for the expanded "patient experience model" (PEM) that includes these components.
The goal of publishing the PEM was to encourage our colleagues and clients to think beyond the “disease and treatment experience” to a more holistic understanding of the patient. And to stimulate debate on what additional components need to be considered to ensure the generalizability of patient experience data. Feel free to drop us your thoughts to help us develop the next iteration!